Address
Novartis Venture Funds
Novartis International AG WSJ-200.220 P.O. Box
4002 Basel
Switzerland
Phone
Industry
Recent investment activity
Tags
KANDO id: 30987
Company type
The corporate venturing arm of Novartis.Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 49Company | Profile | Country | Date Sort descending | Funding | ||
---|---|---|---|---|---|---|
Portaero Inc | N/A | |||||
Ablation Frontiers Inc | Medical device company that has developed and marketed cardiac ablation devices. | N/A | ||||
Panomics Inc | Develops novel cell-based assays and tools to enable multiplexed measurements of molecular events in a quantitative and scalable manner | N/A | ||||
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | Seed Initial investment | ||||
Forma Therapeutics Inc | N/A | |||||
Okairos AG | N/A | |||||
Lumenos Inc | Provider of consumer-driven health care plans. | N/A | ||||
Autonomic Technologies Inc | N/A | |||||
Avila Therapeutics Inc | A biotechnology company, pioneering a method to discover and develop new small-molecule medicines that achieve 'protein silencing'. | N/A | ||||
Viamet Pharmaceuticals Inc | N/A | |||||
Advanced Animal Diagnostics Inc | Develops rapid diagnostic tools to detect and manage disease states, reproductive, nutritional and overall health status of livestock animals. | N/A | ||||
LigoCyte Pharmaceuticals Inc | N/A | |||||
Proteus Biomedical Inc | Cardiac diagnostic devices | N/A | ||||
Celladon Corp | N/A | |||||
Alnylam Pharmaceuticals Inc | N/A | |||||
IRX Therapeutics Inc | N/A | |||||
Aileron Therapeutics Inc | Developing a breakthrough proprietary peptide technology platform | N/A | ||||
Tokai Pharmaceuticals Inc | Developer of prostate cancer drugs | N/A | ||||
Nereus Pharmaceuticals Inc | Series B | |||||
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | N/A Initial investment | ||||
Catalyst Biosciences Inc | Developer of catalytic biopharmaceutical products based on engineered human proteases. | Series A | ||||
Nereus Pharmaceuticals Inc | N/A | |||||
Catalyst Biosciences Inc | Developer of catalytic biopharmaceutical products based on engineered human proteases. | Series B | ||||
Sirtris Pharmaceuticals Inc | Series C | |||||
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B Initial investment |
Pagination
Team
Employee | Position | |||
---|---|---|---|---|
Florent Gros | [email protected] | |||
Rudolf Gygax | [email protected] |